Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia

Barton, James C.; Jones, S. Christopher; Lamberth, Wade C.; Reymann, Michael T.; Scott, Varian C.

doi:10.1002/ajh.10186

Cited by 18 publications

(11 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No patients who developed dasatinib-associated pleural or pericardial effusions had a history of effusions during imatinib therapy. There are occasional reports of imatinib related pleural effusions in the literature, frequently in association with pericardial effusion and most commonly involving patients treated with higher doses of imatinib [40,41]. In one report of three CML patients who developed concomitant pericardial and pleural effusions during treatment with higher dose imatinib the effusions were preceded by a period of weight gain and resolved rapidly on discontinuation of imatinib [40].…”

Section: Other Tkis Associated With Pleural and Pericardial Effusionsmentioning

confidence: 92%

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

et al. 2009

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

show abstract

Section: Other Tkis Associated With Pleural and Pericardial Effusionsmentioning

confidence: 92%

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

et al. 2009

View full text Add to dashboard Cite

show abstract

“…35,36 In addition to peripheral and facial edema, therapy has been associated with pleural and pericardial effusions. 35,37,38 Coleman et al reported edema in 14% of patients and ascites in 10% of patients (grade 3 in 2 of 3 patients). New-onset ascites in ovarian cancer generally is interpreted as disease progression.…”

Section: Discussionmentioning

confidence: 99%

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

Posadas

Kwitkowski²,

Kotz³

et al. 2007

Cancer

View full text Add to dashboard Cite

The morphology of the telencephalon displays great diversity among different vertebrate lineages. Particularly the everted telencephalon of ray‐finned fishes shows a noticeably different morphology from the evaginated telencephalon of nonray‐finned fishes and other vertebrates. This makes the comparison between the different parts of the telencephalon of ray‐finned fishes and other vertebrates difficult. Based on neuroanatomical, neurochemical, and connectional data no consensus on the subdivisions of the adult telencephalon of ray‐finned fishes and their relation to nuclei in the telencephalon of other vertebrates has been reached yet. For tetrapods, comparative expression pattern analysis of homologous developmental genes has been a successful approach to clarify homologies between different parts of the telencephalon. In the larval zebrafish, subdivisions of the subpallium have been proposed using conserved developmental gene expression. In this study, we investigate the subdivisions of the adult zebrafish telencephalon by analyzing the expression pattern of conserved molecular marker genes. We identify the boundary between the pallium and subpallium based on the complementary expression of dlx2a, dlx5a in the subpallium and tbr1, neurod in the pallium. Furthermore, combinatorial expression of Isl, nkx2.1b, lhx1b, tbr1, eomesa, emx1, emx2, and emx3 identifies striatal‐like, pallidal‐like, and septal‐like subdivisions within the subpallium. In contrast to previous models, we propose that the striatum and pallidum are stretched along the rostrocaudal axis of the telencephalon. Further, the septal nuclei derive from both the pallium and subpallium. On this basis, we present a new model for the subdivisions of the subpallium in teleost fish. J. Comp. Neurol. 520:633–655, 2012. © 2011 Wiley Periodicals, Inc.

show abstract

“…These are the only two known cases of cerebral edema among 14,000 patients treated worldwide [37]. In a reported case of cardiac tamponade relieved with surgical drainage, edema symptoms resolved 2 weeks postoperatively with diuretic therapy and discontinuation of imatinib [38].…”

Section: Edemamentioning

confidence: 99%

“…Monitoring of body weight, heart-and lung-associated signs and symptoms, as well as peripheral tissue tone can facilitate early detection of possible fluid retention in patients receiving imatinib [35,36,38]. All patients, especially the elderly or those with cardiac or renal impairment, should be monitored particularly closely for edema and fluid retention not responding optimally to diuretics.…”

Section: Edemamentioning

confidence: 99%

Indications for Imatinib Mesylate Therapy and Clinical Management

2004

View full text Add to dashboard Cite

Imatinib mesylate (Gleevec ® , Glivec ® , formerly STI571; Novartis Pharma AG; Basel, Switzerland) is a rationally-designed, molecularly-specific oral anticancer agent that selectively inhibits several protein tyrosine kinases central to the pathogenesis of human cancer. It has demonstrated remarkable clinical efficacy in patients with chronic myeloid leukemia and malignant gastrointestinal stromal tumors. Treatment with imatinib is generally well tolerated, and the risk for severe adverse effects is low. Adverse effects most commonly include mild-to-moderate edema, nausea and vomiting, diarrhea, muscle cramps, and cutaneous reactions. Hepatic transaminase level elevations and myelosuppression occur less frequently and resolve with interruption of imatinib therapy. In general, the incidence and severity of adverse effects tend to correlate with imatinib dose and, in chronic myeloid leukemia patients, the phase of disease; but, patient age and other factors are also associated with some types of reactions. With prompt and appropriate intervention, adverse effects in imatinib-treated patients have proven to be manageable across the spectrum of severity, and they seldom require permanent cessation of therapy. Dose reduction is not usually necessary, and reduction to subtherapeutic levels is not recommended.

show abstract

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia

Cited by 18 publications

References 3 publications

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

Indications for Imatinib Mesylate Therapy and Clinical Management

Contact Info

Product

Resources

About